Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Trial Profile

A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cobimetinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Gastric cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Small cell lung cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate 032
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 19 Jan 2024 This trial has been completed in Denmark.
    • 20 Dec 2023 Results assessing unanchored population-adjusted indirect comparisons methods through a case study in third-line small-cell lung cancer comparing nivolumab to standard of care based on a single-arm phase II trial (CheckMate 032) and real-world study (Flatiron) for time-to-event outcomes using regression adjustment, inverse odds weighting, and doubly robust methods with either individual patient or aggregate data, published in the Value in Health.
    • 13 Dec 2023 Planned End Date changed from 31 Dec 2023 to 30 May 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top